Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Model for End-Stage Liver Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Model for End-Stage Liver Disease. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-000963-15 Sponsor Protocol Number: MATCH0.1 Start Date*: 2016-01-19
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: MAcrophage Therapy for Liver Cirrhosis (MATCH)
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-005012-42 Sponsor Protocol Number: 747-302 Start Date*: 2016-01-05
    Sponsor Name:Intercept Pharmaceuticals Inc.
    Full Title: A Phase 4, Double Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis. The COBALT S...
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Prematurely Ended) AT (Prematurely Ended) BE (Completed) DK (Prematurely Ended) FI (Prematurely Ended) GB (GB - no longer in EU/EEA) EE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing) DE (Completed) BG (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010335-41 Sponsor Protocol Number: RRK3728 Start Date*: 2009-06-30
    Sponsor Name:University of Birmingham
    Full Title: A MULTICENTRE, PHASE II, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF REPEATED AUTOLOGOUS INFUSIONS OF G-CSF MOBILISED CD133+ BONE MARROW STEM CELLS IN PATIENTS WITH CIRRHOSIS
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    14.1 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    14.1 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10064844 Compensated cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001139-22 Sponsor Protocol Number: POPH Start Date*: 2011-06-29
    Sponsor Name:Medizinische Universität Graz, Klin. Abteilung für Gastroenterologie und Hepatologie
    Full Title: AMBRISENTAN FOR TREATMENT OF PORTOPULMONARY HYPERTENSION (POPH): A PILOT STUDY
    Medical condition: Portopulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome HPS are present in a considerable number of patients with compensated cirrhosis. Treatment of PoPH with ambrisentan is well tolerated...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10067281 Portopulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003051-11 Sponsor Protocol Number: HEP102-DHELIVER Start Date*: 2019-12-04
    Sponsor Name:Promethera Therapeutics
    Full Title: Randomized, placebo-controlled, double blind, multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) - DHELIVER
    Medical condition: Cirrhotic patients who are hospitalized for Acute on chronic liver failure (ACLF), ACLF combines an acute deterioration of liver function in an individual with pre-existing chronic liver disease a...
    Disease: Version SOC Term Classification Code Term Level
    24.0 10019805 - Hepatobiliary disorders 10077305 Acute on chronic liver failure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) LV (Trial now transitioned) LT (Trial now transitioned) SK (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) PL (Trial now transitioned) PT (Completed) EE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) SI (Completed) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001762-13 Sponsor Protocol Number: 747-401 Start Date*: 2018-08-01
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepa...
    Medical condition: Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) HU (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005851-40 Sponsor Protocol Number: TPL104054 Start Date*: 2008-05-07
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with C...
    Medical condition: Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008953 Chronic liver disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000821-37 Sponsor Protocol Number: GS-US-416-2124 Start Date*: 2017-02-06
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic H...
    Medical condition: Alcoholic Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001240-61 Sponsor Protocol Number: allo-APZ2-ACLF-II-01 Start Date*: 2018-12-19
    Sponsor Name:RHEACELL GmbH & Co. KG
    Full Title: An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF)
    Medical condition: Acute-on-Chronic Liver Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10077305 Acute on chronic liver failure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001983-31 Sponsor Protocol Number: GT-031 Start Date*: 2021-05-04
    Sponsor Name:Galectin Therapeutics Inc.
    Full Title: A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Es...
    Medical condition: Esophageal Varices in NASH Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10009214 Cirrhosis of liver without mention of alcohol LLT
    21.1 100000004856 10055489 Esophageal varices in cirrhosis of liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023245-30 Sponsor Protocol Number: INMI/001/10 Start Date*: 2011-02-02
    Sponsor Name:ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI
    Full Title: Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis
    Medical condition: Chonic hepatitis HCV-related
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019805 SOC
    9.1 10038359 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002325-38 Sponsor Protocol Number: A4250-008 Start Date*: Information not available in EudraCT
    Sponsor Name:Albireo AB
    Full Title: An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)
    Medical condition: Progressive Familial Intrahepatic Cholestasis Types 1 and 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10076033 Progressive familial intrahepatic cholestasis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) ES (Prematurely Ended) IT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004986-38 Sponsor Protocol Number: 337HNAS20011 Start Date*: 2022-01-04
    Sponsor Name:Inventiva S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatiti...
    Medical condition: Non-alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) AT (Completed) HU (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004754-15 Sponsor Protocol Number: 3152-201-002 Start Date*: 2017-06-05
    Sponsor Name:Tobira Therapeutics, Inc., a subsidiary of Allergan plc
    Full Title: Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH)
    Medical condition: Liver fibrosis in Subjects with Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) ES (Prematurely Ended) HU (Prematurely Ended) AT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000581-38 Sponsor Protocol Number: 17/0894 Start Date*: 2019-07-29
    Sponsor Name:University College London Comprehensive Clinical Trials Unit
    Full Title: ASEPTIC: Primary Antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis
    Medical condition: Spontaneous bacterial peritonitis infection in patients with advanced liver disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10061135 Spontaneous bacterial peritonitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-000965-34 Sponsor Protocol Number: E5501-G000-310 Start Date*: 2014-05-27
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia ...
    Medical condition: Thrombocytopenia in Patients with Chronic Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    18.0 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    18.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    18.0 10005329 - Blood and lymphatic system disorders 10039884 Secondary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed) GB (Completed) AT (Completed) HU (Completed) ES (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004287-30 Sponsor Protocol Number: LAL-CL06 Start Date*: 2014-06-19
    Sponsor Name:Alexion Pharmaceuticals inc
    Full Title: A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency
    Medical condition: Lysosomal Acid Lipase Deficiency (LALD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10024579 Lysosomal storage disorders HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) BE (Completed) HR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004534-38 Sponsor Protocol Number: C928-011 Start Date*: 2021-10-11
    Sponsor Name:DURECT Corporation
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2b Study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis
    Medical condition: Alcoholic hepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001639-10 Sponsor Protocol Number: 787-201 Start Date*: 2023-06-09
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subje...
    Medical condition: Severe Alcohol-Associated Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002279-13 Sponsor Protocol Number: MGL-3196-19 Start Date*: 2023-02-28
    Sponsor Name:Madrigal Pharmaceuticals, Inc.
    Full Title: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepati...
    Medical condition: Non-alcoholic Steatohepatitis (NASH) Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10009214 Cirrhosis of liver without mention of alcohol LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:31:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA